Диссертация (1140673), страница 15
Текст из файла (страница 15)
Report №.: 3001058.20. Antila S., Kivikko M. Pharmacokinetics of levosimendan and its metabolitesduring and after a one week continuous infusion of levosimendan topatients with heart failure. Group 4 (24 hour infusion). Internal report:Orion Pharma; 2000. Report №.: 3001058.21. Antila S., Kivikko M. Pharmacokinetics of levosimendan and its metabolitesduring and after a one week continuous infusion of levosimendan topatients with heart failure. Group 3. Internal report: Orion Pharma; 2000.Report №.: 3001058.9522. Antila S., WikbergT., Vuorela A., RantanenS.
Excretion balance andpharmacokinetics of radiocarbon after a single intravenous infusion of 14Clabelled levosimendan in healthy subjects (An overview of the excretionandmetabolismof14C-labelledlevosimendanincludingpharmacokineticsof levosimendan and metabolites OR-1855 and OR1896).Internal report: Orion Pharma; 2000 May 2. Report №.: 3001054.23. Bassani R.A., Bassani J.W., Bers D.M. et al.: Relaxation in ferret ventricularmyocytes: role of the sarcolemmal Ca++ATPase. Pflugers Atchiv 1995;430:573-8.24. Baysal A, Yanartas M, Dogukan M et al., N. Levosimendan improves renaloutcome in cardiac surgery: a randomised trial, J.
Cardiothorac. Vasc.Anesth. 28 (2014) 586–594.25. Bers D.M., Measurment of Calcium transport in heart using modernapproaches. New Horizons 1996; 4:36-44.26. Bers D.M.: Calcium fluxes involved in control of cardiac myocytecontraction. Circ Res 2000; 87:275-81.27. Bers D.M.: Cardiac excitation-contraction coupling. Nature 2001; 415:19820528. Binkley P.F., Nunziata E., Hatton P.S., Leier C.V.
The positive inotropicagent levosimendan mediates increased cardiac output without progressionof sympathovagal imbalance in patients with heart failure. Circulation2000; 18 (suppl): 102.29. Blinks JR, Endoh M.: Modification of myofibrillar responsiveness to Ca2+as an inotropic mechanism. Circulation 1986; 73:III85-III98.30. Bocchi E., Guimarres G., Moura L, Vilas-Boas F., BELIEF Study Group.Markers of levosimendan efficacy in the treatment of congestive heartfailure - The Brazilian evaluation of levosimendan infusion efficacy(BELIEF Study): a prospective multicenter study.
Eur J Heart Fail 2003; 2(supplement): 162.9631. Bowman P., Haikala H., Paul R.J. Levosimendan, a calcium sensitizer incardiac muscle, induces relaxation in coronary smooth muscle throughcalcium desensitization. J Pharmacol Exp Ther 1999; 288: 316-325.32. Brixius K., Reicke S., Schwinger R.H.G. Beneficial effects of the Ca2+sensitizer levosimendan in human myocardium. Am Journal of PhysiologyHeart and Circulatory Physiology 2002; 282: H131-H137.33. Caimmi P.P., Kapetanakis E.I., Beggino C., et al. Management of AcuteCardiac Failure by Intracoronary Administration ofLevosimendan. JCardiovasc PharmacolTM. 2011;58:246-25334. Cammarata G.A., Weil M.H., Sun S., et al. Levosimendan improvescardiopulmonary resuscitation and survival by K(ATP) channel activation.J Am Coll Cardiol 2006;47:1083–5.35.
Chen Q., Camara A.K., Rhodes S.S., et al. Cardiotonic drugs differentiallyalter cytosolic [Ca2+] to left ventricular relationships before and afterischemia in isolated guinea pig hearts. Cardiovasc Res 2003;59:912–25.36. Cleland J., Nieminen M., Kivikko M. The effect of levosimendan on longterm mortality of patients with low-output heart failure and renalimpairment. Eur J Heart Fail 2003; 2 (supplement): 99.37. Cleland JG, Swedberg K, Follath F et al. The EuroHeart Failure surveyprogramme a survey on the quality of care among patients with heartfailure in Europe. Part 1: patient characteristics and diagnosis.Eur Heart J.2003;24 (5):442–463.38. Colucci W.S., Slawsky M.T., Kivikko M.
Prolonged effects of a 24-hourinfusion of the calcium sensitiser levosimendan in patients with severeheart failure. Eur J Heart Fail 2002; 1 (supplement): 80.39. Cowie MR, Fox KF, Wood DA et al. Hospitalization of patients with heartfailure: a population-based study. Eur Heart J. 2002;23 (11):877–885.Critical Care, 201418:503 DOI: 10.1186/s13054-014-0503-3Critical Care201418:503 DOI: 10.1186/s13054-014-0503-39740. De Hert S.G., Lorsomradee S., vanden Eede H., et al., A Randomized TrialEvaluating Different Modalities of Levosimendan Administration inCardiac Surgery Patients With Myocardial Dysfunction Journal ofCardiothoracic and Vascular Anesthesia, Vol 22, No 5 (October), 2008: pp699-70541.
Diaz M.E. Graham H.K., O’Neill S.C., et al. The control of carcoplasmicreticulum Ca2+content in cardiac muscle. Cell Calcium 2005; 38:391-6.42. Dickstein K., Cohen-Solal A., Filippatos G., et al: ESC guidelines for thediagnosis and treatment of acute and chronic heart failure 2008: The TaskForce for the Diagnosis and Treatment of Acute and Chronic Heart Failure2008 of the European Society of Cardiology. Developed in collaborationwith the heart failure association of the ESC (HFA) and endorsed by theEuropean Society of Intensive Care Medicine (ESICM).
Eur Heart J29:2388-2442, 200843. du Toit E.F., Genis A., Opie L.H., et al. A role for the RISK pathway andK(ATP) channels in pre- and post-conditioning induced by levosimendanin the isolated guinea pig heart. Br J Pharmacol 2008;154:41–50.44. Edes I., Kiss E., Kitada Y., et al. Effects of levosimendan, a cardiotonicagent targeted to troponin C, on cardiac function and on phosphorylationand Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum inguinea pig heart.
Circ Res 1995;77:107–13.45. Endoh M., Hori M.: Acute heart failure: inotropic agents and their clinicaluses. Expert Opin Pharmacother 2006; 7:2179-20246. Erdei N., Papp Z., Pollesello P., et al.: The levosimendan metabolite OR1896 elicits vasodilation by activating the K (ATP) and BK(Ca) channels inrat isolated arterioles.
Br J Pharmacol 148:696-702, 200647. Fishbein MC, Wang T, Matijasevic M. et al. Myocardial tissue troponins Tand I. An immunohistochemical study in experimental models ofmyocardial ischemia. Cardiovasc Pathol. 2003;12:65–719848. Follath F., Cleland J.G., Just H., et al. Efficacy and safety of intravenouslevosimendan compared with dobutamine in severe low-output heart failure(the LIDO study): a randomised double-blind trial. Lancet 2002;360:196202.49. Fonarow G.C., Heywood J.T., Heidenreich P.A., et al.: Temporal trends inclinical characteristics, treatments and outcomes for heart failurehospitalizations, 2002 to 2004: findings from Acute Decompensated HeartFailure National Registry (ADHERE). Am Heart J 2007; 153: 1021-8.50.
Franco F., Gonsalves F., Castro G. etal. Levosimendan improvesneurohumoral status in patients with advanced heart failure. Eur J HeartFail 2003; 2 (supplement): 169.51. Gandham R., Syamasundar A., Ravulapalli H. et al. A comparison ofhemodynamic effects of levosimendan and dobutamine in patientsundergoing mitral valve repair/replacement for severe mitral stenosis //Ann.
Card. Anaesth. 2013. Vol. 16. P. 11–15.).52. Garcia-Alvarez M, Marik P., Bellomo R et al. Sepsis- assicated lactatemia53. Garcia-Alvarez M, Marik P., Bellomo R et al. Sepsis- assicated lactatemia54. Garratt C, Sarapohja Т., Wesby-Van Swaay E. Randomized multicenterevaluation of intravenous levosimendan efficacy versus placebo in shortterm treatment of decompensated chronic heart failure. Internal report:Orion Pharma; 2003. Report №.: 3001069.55. Giannakoulas G., Giannoglou G., Vassilikos V., et al.
Clinical significanceof acute neurohormonal response after levosimendan treatment. Am JCardiol 2006;98: 1123–456. Goetzenich A., Hatam N., Preuss S., et al. The role of hypoxia-induciblefactor-1αandvascularendothelialgrowthfactorinlate-phasepreconditioning with xenon, isoflurane and levosimendan in ratcardiomyocytes. Interact Cardiovasc Thorac Surg. 2014 Mar;18(3):321-89957. Greco T., Calabrò M.G., Covello R.D., et al., Bayesian network metaanalysis on the effect of inodilatory agents on mortality.
Br J Anaesth.2015 May;114(5):746-5658. Grossini E., Caimmi P.P., Molinary C., et al. Hemodynamic effect ofintracoronary administration of levosimendan in the anesthetized pig. JCardiovasc Pharmacol. 2006;46:333-342.59. Gruhn N., Nielsen-KudskJ.E.,Theilgaard S. etal. Coronary vasorelaxanteffect of levosimendan, a new inodilator with calcium-sensitizingproperties. J Cardiovasc Pharmacol 1998; 31: 741-749.60. Haikala H., Kaheinen P., Levijoki J., Linden IB. The role of cAMP- andcGMP-dependent protein kinases in the cardiac actions of the new calciumsensitizer, levosimendan. Cardiovasc Res 1997; 34: 536-546.61.
Haikala H., Kaivola J., Nissinen E. et al. Cardiac troponin С as a targetprotein for a novel calcium sensitizing drug, levosimendan. J Mol CellCardiol 1995; 27:1859-1866.62. Haikala H., Levijoki J., Linden I-B. Effect of levosimendan via troponin С iscontrolled by intracellular calcium load and calcium influx.
J Mol CellCardiol 1995; 27: A109.63. Haikala H., Linden I-B. Mechanisms of action of calciumsensitizing drugs. JCardiovasc Pharmacol 1995; 26 (Suppl. 1): 10-9.64. Haikala H., Nissinen E., Etemzadeh E., et al.: Troponin C-mediated calciumsensitization induced by levosimendan does not impair relaxation. JCardiovasc Pharmacol 1995; 25:794-801.65. Harrison R.W., Hasselblad V., Mehta R.H., et al. Effect of Levosimendan onSurvival and Adverse Events After Cardiac Surgery: A Meta-Analysis,Journal of Cardiothoracic and Vascular Anesthesia, vol. 27, No6(December), 2013:pp 1224–123266. Hasenfuss G., Holubarsch H., Blanchard E.
et al. Energetic aspects ofinotropic interventions in rat myocardium. Basic Res Cardiol 1987; 82:251-259.10067. Hasenfuss G., Pieske В., Castell M. etal. Influence of the novel inotropicagent levosimendan on isometric tension and calcium cycling in failinghuman myocardium. Circulation 1998; 98: 2141-2147.68. Hasenfuss G., Pieske В., Kretschmann B. etal. Effects of calcium sensitizerson intracellular calcium handling and myocardial energetics.
J CardiovascPharmacol 1995; 26 (Suppl. 1): 45-51.69. Hogg K, Swedberg K, McMurray J. Heart Failure with preserved leftventricular systolic function. Epidemiology, Clinical Characteristics, andPrognosis. J Am Coll Cardiol. 2004;43 (3):317–327.70. Honisch A., Theuring N., Ebner B., et al. Postconditioning withlevosimendan reduces the infarct size involving the PI3K pathway andKATP-channel activation but is independent of PDE-III inhibition. BasicRes Cardiol 2009;105:155–67.71. Jamali I.N., Kersten J.R., Pagel P.S., Hettrick D.A., Warltier D.C.Intracoronary levosimendan enhances contractile function of stunnedmyocardium. Anesth Analg 1997; 85: 23-29.72.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
